Virtus LifeSci Biotech Clinical Trials ETF
18 hedge funds and large institutions have $14.7M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
65% less capital invested
Capital invested by funds: $42.1M → $14.7M (-$27.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
18
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$638K | |
| 2 | +$453K | |
| 3 | +$320K | |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$262K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$201K |
Top Sellers
| 1 | -$16.6M | |
| 2 | -$6.75M | |
| 3 | -$4.87M | |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$811K |
| 5 |
VF
Virtu Financial
New York
|
-$369K |